Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a
coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …

Importance Gut dysbiosis impairs response to immune checkpoint inhibitors (ICIs) and can
be caused by broad-spectrum antibiotic (ATB) therapy. Objective To evaluate whether there …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Background & Aims Overall survival (OS) is a composite clinical endpoint in hepatocellular
carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating …

Preliminary evidence of safety and tolerability of atezolizu... : Hepatology Preliminary
evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with …

The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There
is uncertainty as to the contribution of patients' demographics and oncologic features to …

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have
been effective in only a small subset of patients and a principal mechanism underlying …